Noah Stansfield

The treated patient achieved an overall partial response of 72% in tumor regression.

A multisite phase 1 clinical trial for NT-I7 is underway in patients with relapsed/refractory large B-cell lymphoma.

CTX130 is also being investigated for the treatment of r/r renal cell carcinoma in a phase 1 clinical trial called COBALT-RCC (NCT04438083).

Among treated patients, 42% achieved 5-year event free survival.